Navigation Links
Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome
Date:1/15/2014

ed by an additional four weeks of open label treatment, the results of which are not yet available.  The trial enrolled 17 patients with genetically confirmed PWS, including 11 women and 6 men, with a mean age of 33.9 years, and mean body mass index (BMI) of 31.4 kg/m2.  Beloranib appeared to be safe and very well-tolerated.  All 17 patients completed the randomized treatment part of the trial and all opted to continue into and completed the four-week open label extension.

About Prader-Willi Syndrome
Prader-Willi syndrome (PWS), the most common known genetic cause of life-threatening obesity, causes constant hunger that drives PWS patients to gain more weight on fewer calories than the average person.  As a result, many of those affected become morbidly obese before the age of five.  There is currently no cure for this disease.  Although the cause is complex, it results from a deletion or loss of function of a cluster of genes on the 15th chromosome.  PWS typically causes low muscle mass and function, short stature, incomplete sexual development, and a chronic feeling of hunger that, coupled with a metabolism that utilizes drastically fewer calories than normal, can lead to excessive eating and life-threatening obesity.  PWS occurs in males and females equally and in all races, with the same incidence around the world.  Prevalence estimates have ranged from 1:8,000 to 1:50,000 with the most likely figure being approximately 1:40,000.  To the best of our knowledge, prevalence is about 5,000-7,000 people in the United States needing treatment.  You can learn more through the Prader-Willi Syndrome Association website at www.pwsausa.org.

About Beloranib
Beloranib is the first compound in its class that works by targeting a key enzyme called MetAP2 that controls the production and utilization of fatty acids.  Inh
'/>"/>

SOURCE Zafgen, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Zafgen Announces Initiation of Phase 2a Clinical Development with Beloranib in Obesity
2. Zafgen Secures $21 Million in Series D Financing
3. Zafgen Announces New Weight Loss and Safety Data from Phase 2 Study of Beloranib in Obesity at Obesity Week 2013
4. Zafgen Secures $45 Million in Series E Financing
5. Zafgen Appoints Chief Commercial Officer and New Member of Board of Directors
6. Precision Optics Corporation Announces $1 Million Order for Microprecision™ Based Endoscopes
7. Young Innovations, Inc. Announces Record Sales and EPS for the Quarter Ended March 31, 2012
8. JDRF Announces Research Collaboration with Dexcom, Inc. to Develop "Smart Transmitter" Technology to Accelerate Artificial Pancreas Studies
9. Misonix Announces New Distribution Agreement For Panama
10. University of Maryland BioPark Announces MedImmunes Dr. Bahija Jallal as Newest Member of Board of Directors for UM Health Sciences Research Park
11. Novelos Therapeutics Announces Successful Completion of First Cohort In Lung Cancer Trial With I-124-CLR1404 (LIGHT) Cancer-Targeted PET Imaging Agent at UW Carbone Cancer Center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  Cephasonics, a technology-innovation leader with a game-changing embedded-ultrasound ... Ultrasound Box™-1), the first product in a new family ... Cephasonics for purchase by companies to rebrand with their ... showcasing the cQUB-1 for the first time at CMEF ... Chongqing, China from October 23 to 26. ...
(Date:10/22/2014)... 22, 2014  Quest Diagnostics (NYSE: DGX ... today announced that its Board of Directors has elected ... effective December 1, 2014. Including Dr. Leiden, the Board ... Chairman, President and CEO of Vertex Pharmaceuticals.   Dr. ... commercial experience in the pharmaceutical and biotechnology industries as ...
(Date:10/22/2014)... 22, 2014 Antigen Discovery Inc. (ADi), a ... , announced the receipt of a National Institutes of ... from the National Institute of Dental and Craniofacial Research (NIDCR). ... a Pan-HIV Protein Microarray Chip, which will contain every ... and aid in the development of safe and effective ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 2Quest Diagnostics Adds Jeffrey M. Leiden, M.D., Ph.D., to Board of Directors 3Biomarker Discovery Company, Antigen Discovery Inc., Awarded an NIH Phase I Small Business Innovation Research Grant to Develop a Pan-HIV Protein Microarray Chip 2
... 2011  Seventeen of the 19 medical-surgical suppliers and healthcare ... 25 for 2011 work with GHX to automate and ... them achieve high-quality patient care at optimal economic cost. ... and providers recognized by Gartner in the Top 25 ...
... 2011 ULURU Inc. (NYSE AMEX: ... of the previously announced European license for Altrazeal®, with a ... Zealand. Extending the European territory to include ... is a common registration process and the marketing strategy and ...
Cached Medicine Technology:GHX Salutes 17 Healthcare Organizations That Use Its Technology for Inclusion on a Leading Analyst Firm's 2011 Healthcare Supply Chain Top 25 List 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 2ULURU Inc. Extends the European Altrazeal® License to Include Australia and New Zealand 3
(Date:10/22/2014)... 2014 The Louis W. ... dedicated to distribute health information technology innovation to ... announced the development of six key guiding principles ... receiving healthcare. These are an expansion of the ... care that is respectful of and responsive to ...
(Date:10/22/2014)... 2014 Best Cheap Hosting USA is ... The site has recently announced that iPower ( http://www.best-cheap-hosting-usa.com/go/iPower/ ... people from around the world. , “iPower is one ... and is providing various kinds of useful products for ... on offering excellent customer service and a number of ...
(Date:10/22/2014)... 2014 Lintelus, Inc., an event software ... of Sales, will be speaking on the subject of ... on October 28, at the Holiday Inn in New ... as well as a Tech Demo at 12:45pm, to ... a more engaging event experience. , The Annual Meetings ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, ... (IVF) are only about half as likely as white women ... research indicates, and the racial disparity persists even when donor ... of white patients became pregnant after IVF, compared to about ... IVF cycles over two years to tease out the impact ...
(Date:10/22/2014)... -- Measures taken by Firestone officials at the company,s ... limited the spread of the disease there and could ... Rubber Co. provides health services to about 80,000 employees, ... communities. Between Aug. 1 and Sept. 23, there ... 80,000 people. That incidence rate of 0.09 percent was ...
Breaking Medicine News(10 mins):Health News:The Sullivan Institute for Healthcare Innovation Announces Release of Guiding Principles for Patient Experience-Centered Care 2Health News:Best Cheap Hosting USA Has Recently Announced The Best Cheap Web Hosting Companies In 2014 2Health News:Jay Cormier, Sr. Vice President of Sales for Lintelus, Speaks about Event Technology Integration at Meetings Technology Expo in NYC 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 2Health News:Black Women Fare Worse With Fertility Treatments, Study Says 3Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2
... for women than men, major study finds , MONDAY, Aug. ... significantly increased risk for head and neck cancers such as ... and throat, says a U.S. National Cancer Institute study that ... women between 1995 and 2000. , The analysis revealed that ...
... the market in 2004 because they caused dangerous heart problems ... Hla at the University of Connecticut, may now have figured ... study will be published online in the The Journal of ... these drugs is an enzyme called COX-2, which is produced ...
... Smoking significantly increases the risk for head and neck ... anatomic site. Published in the October 1, 2007 issue ... Society, a large, prospective study confirmed strong associations between ... head and neck in both genders. , Cancers of ...
... of study to aid researchers in hunt for treatments ... public online database launched recently may help speed efforts ... bipolar disorder, a mood disorder commonly marked by alternating ... Disorder Phenome Database -- a joint project of the ...
... WESTCHESTER, Ill. For most children and teens, the beginning ... Not only will they be hitting the books again ... also participate in after-school activities. More research is emerging ... the number of children and teens who are considered obese ...
... study suggests that where the fat is stored is key ... a person is destined to develop diabetes, experiments in mice ... is stored. , Mice that overate and were very ... hormones let them store extra calories in fat tissue rather ...
Cached Medicine News:Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 2Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 3Health News:AASM encourages those student-athletes at risk for developing osa to visit a sleep clinic 4Health News:Obesity Doesn't Always Equal Diabetes 2Health News:Obesity Doesn't Always Equal Diabetes 3
... face is the most widely used contrast sensitivity ... four (4) rows of sine-wave gratings. At the ... these gratings test the spatial frequencies of 3, ... a full contrast sensitivity curve, which is very ...
The Wills Eye Manual, Fourth Edition has been updated to include the newest drugs, procedures, and treatment protocols. Clinicians will have instant access to current information on diagnosis and tre...
... those involved with healthcare decisions to keep ... evidence in their field of interest - ... as the volume of evidence increases. Cochrane ... best single source available for continually updated ...
... Clinical Orthopedics 2007 includes ... therapeutic and rehab info as ... text is very extensive, it ... information. Great for any primary ...
Medicine Products: